Global Phenprocoumon Market Insights, Forecast to 2028

Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism).
Market Analysis and Insights: Global Phenprocoumon Market
Due to the COVID-19 pandemic, the global Phenprocoumon market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 5 mg accounting for % of the Phenprocoumon global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Venous Thrombosis segment is altered to an % CAGR throughout this forecast period.
China Phenprocoumon market size is valued at US$ million in 2021, while the US and Europe Phenprocoumon are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Phenprocoumon landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Phenprocoumon include Novartis, Mylan, Teva, Roche, Aspen Pharmacare, Acis Arzneimittel, Wörwag Pharma and Divis Labs, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Phenprocoumon Scope and Segment
Phenprocoumon market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Phenprocoumon market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
5 mg
10 mg
25 mg
50 mg
Segment by Application
Venous Thrombosis
Thromboembolism
Pulmonary Embolism
Others
By Company
Novartis
Mylan
Teva
Roche
Aspen Pharmacare
Acis Arzneimittel
Wörwag Pharma
Divis Labs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE